Algert Global LLC Trims Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Algert Global LLC decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 61.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,714 shares of the medical equipment provider's stock after selling 77,626 shares during the period. Algert Global LLC owned about 0.07% of Lantheus worth $5,456,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock worth $458,271,000 after buying an additional 389,828 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Lantheus by 30.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 50,078 shares of the medical equipment provider's stock worth $3,116,000 after acquiring an additional 11,696 shares during the period. 2Xideas AG purchased a new stake in Lantheus during the 1st quarter valued at about $10,642,000. Tidal Investments LLC raised its holdings in shares of Lantheus by 68.1% during the first quarter. Tidal Investments LLC now owns 27,570 shares of the medical equipment provider's stock worth $1,716,000 after purchasing an additional 11,168 shares during the last quarter. Finally, Hancock Whitney Corp boosted its stake in shares of Lantheus by 265.6% in the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider's stock worth $1,254,000 after buying an additional 14,639 shares during the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Price Performance

Shares of LNTH stock traded up $0.44 during trading on Monday, hitting $90.96. 1,343,879 shares of the stock traded hands, compared to its average volume of 1,022,109. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The firm has a market capitalization of $6.32 billion, a P/E ratio of 15.13 and a beta of 0.51. The firm's fifty day moving average price is $103.13 and its 200-day moving average price is $96.93.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on LNTH shares. StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday. JMP Securities lowered their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. Finally, Truist Financial reiterated a "buy" rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.